

# Anna-Lena Volckmar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2891376/publications.pdf>

Version: 2024-02-01

40  
papers

1,368  
citations

430442  
18  
h-index

360668  
35  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2442  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 123-139.  | 1.5 | 155       |
| 2  | Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.   | 1.3 | 152       |
| 3  | Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. <i>International Journal of Cancer</i> , 2019, 144, 848-858.   | 2.3 | 131       |
| 4  | Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and real-life analysis of three larger gene panels. <i>International Journal of Cancer</i> , 2019, 144, 2303-2312.   | 2.3 | 95        |
| 5  | Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. <i>International Journal of Cancer</i> , 2019, 145, 649-661.  | 2.3 | 85        |
| 6  | Variant classification in precision oncology. <i>International Journal of Cancer</i> , 2019, 145, 2996-3010.   | 2.3 | 76        |
| 7  | Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1935-1947.   | 0.5 | 69        |
| 8  | Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. <i>European Journal of Cancer</i> , 2018, 104, 239-242.  | 1.3 | 43        |
| 9  | Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , 2020, 72, 1253-1266.   | 3.6 | 42        |
| 10 | Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival. <i>Cancers</i> , 2019, 11, 124.   | 1.7 | 36        |
| 11 | Genotyping of colorectal cancer for cancer precision medicine: Results from the IPH Center for Molecular Pathology. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 505-521.   | 1.5 | 34        |
| 12 | RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples. <i>Cancers</i> , 2019, 11, 1309.   | 1.7 | 32        |
| 13 | EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trial. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 509-520. | 1.4 | 29        |
| 14 | Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 11-17.   | 1.5 | 27        |
| 15 | Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. <i>International Journal of Cancer</i> , 2019, 145, 2963-2973.   | 2.3 | 24        |
| 16 | Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199650.  | 1.4 | 24        |
| 17 | Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. <i>Pathology</i> , 2018, 50, 703-710.  | 0.3 | 21        |
| 18 | Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.  | 1.5 | 20        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 70-79.   | 1.5 | 19        |
| 20 | Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma. <i>Proteomics - Clinical Applications</i> , 2019, 13, e1800034.   | 0.8 | 19        |
| 21 | Oncogenic driver mutations, treatment, and EGFR-TKI resistance in a Caucasian population with non-small cell lung cancer: survival in clinical practice. <i>Oncotarget</i> , 2017, 8, 77897-77914.   | 0.8 | 19        |
| 22 | The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. <i>ESMO Open</i> , 2021, 6, 100253.  | 2.0 | 17        |
| 23 | Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies. <i>Translational Lung Cancer Research</i> , 2021, 10, 2118-2131.   | 1.3 | 16        |
| 24 | Assigning evidence to actionability: An introduction to variant interpretation in precision cancer medicine. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 303-313.  | 1.5 | 15        |
| 25 | Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. <i>Oncotarget</i> , 2017, 8, 74049-74057.  | 0.8 | 14        |
| 26 | Next generation sequencing of the cellular and liquid fraction of pancreatic cyst fluid supports discrimination of IPMN from pseudocysts and reveals cases with multiple mutated driver clones: First findings from the prospective ZYSTEUS biomarker study. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 3-11. | 1.5 | 14        |
| 27 | Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary. <i>International Journal of Cancer</i> , 2020, 146, 3053-3064.  | 2.3 | 14        |
| 28 | KRAS / GNAS testing by highly sensitive deep targeted next generation sequencing improves the endoscopic ultrasound-guided workup of suspected mucinous neoplasms of the pancreas. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 489-497.  | 1.5 | 13        |
| 29 | PARP inhibition in BRCA2-mutated prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 189-191.   | 0.6 | 12        |
| 30 | High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer – Results from a prospective pilot study using a 37 gene panel. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 637.e17-637.e27.                          | 0.8 | 12        |
| 31 | Immuno-oncology gene expression profiling of formalin-fixed and paraffin-embedded clear cell renal cell carcinoma: Performance comparison of the NanoString nCounter technology with targeted RNA sequencing. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 406-416.   | 1.5 | 10        |
| 32 | RREB1-MKL2 fusion in a spindle cell sinonasal sarcoma: biphenotypic sinonasal sarcoma or ectomesenchymal chondromyxoid tumor in an unusual site?. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 565-570.   | 1.5 | 10        |
| 33 | Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 670483.  | 1.3 | 10        |
| 34 | Knowledge bases and software support for variant interpretation in precision oncology. <i>Briefings in Bioinformatics</i> , 2021, 22, .  | 3.2 | 9         |
| 35 | Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report. <i>Diagnostic Pathology</i> , 2016, 11, 133.  | 0.9 | 8         |
| 36 | Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 214-220.  | 1.5 | 8         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report. Case Reports in Oncology, 2021, 14, 477-482. | 0.3 | 8         |
| 38 | Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field. Lung Cancer, 2021, 154, 131-141.  | 0.9 | 8         |
| 39 | Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers, 2021, 13, 2616.   | 1.7 | 8         |
| 40 | Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 1666-1678.   | 1.3 | 6         |